1145 related articles for article (PubMed ID: 24438970)
1. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
2. Extracorporeal photophoresis: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(6):1-82. PubMed ID: 23074497
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic alternatives in cutaneous T-cell lymphoma.
Holloway KB; Flowers FP; Ramos-Caro FA
J Am Acad Dermatol; 1992 Sep; 27(3):367-78. PubMed ID: 1383293
[TBL] [Abstract][Full Text] [Related]
4. Mycosis fungoides and the Sézary syndrome: pathology, staging, and treatment.
Hoppe RT; Wood GS; Abel EA
Curr Probl Cancer; 1990; 14(6):293-371. PubMed ID: 2245651
[TBL] [Abstract][Full Text] [Related]
5. Mycosis fungoides and the Sézary syndrome: a review of pathogenesis, diagnosis, and therapy.
Kuzel TM; Roenigk HH; Rosen ST
J Clin Oncol; 1991 Jul; 9(7):1298-313. PubMed ID: 2045869
[TBL] [Abstract][Full Text] [Related]
6. [Modern therapy of mycosis fungoides].
Roenigk HH
Hautarzt; 1983 Jun; 34(6):266-72. PubMed ID: 6874333
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous T-cell Lymphomas: A Single-center Retrospective Analysis.
Kaemmerer T; Guertler A; Clanner-Engelshofen BM; Fuchs C; French LE; Reinholz M
Acta Dermatovenerol Croat; 2023 Dec; 31(4):184-190. PubMed ID: 38651844
[TBL] [Abstract][Full Text] [Related]
8. Systemic treatment for cutaneous lymphomas.
Mielke V; Staib G; Sterry W
Recent Results Cancer Res; 1995; 139():403-8. PubMed ID: 7597307
[TBL] [Abstract][Full Text] [Related]
9. Systemic chemotherapy and extracorporeal photochemotherapy for T3 and T4 cutaneous T-cell lymphoma patients who have achieved a complete response to total skin electron beam therapy.
Wilson LD; Licata AL; Braverman IM; Edelson RL; Heald PW; Feldman AM; Kacinski BM
Int J Radiat Oncol Biol Phys; 1995 Jul; 32(4):987-95. PubMed ID: 7607973
[TBL] [Abstract][Full Text] [Related]
10. Deciphering Tumor Cell Evolution in Cutaneous T-Cell Lymphomas: Distinct Differentiation Trajectories in Mycosis Fungoides and Sézary Syndrome.
Jiang TT; Cao S; Kruglov O; Virmani A; Geskin LJ; Falo LD; Akilov OE
J Invest Dermatol; 2024 May; 144(5):1088-1098. PubMed ID: 38036289
[TBL] [Abstract][Full Text] [Related]
11. Mycosis fungoides and Sézary syndrome: a population-wide study on prevalence and health care use in Finland in 1998-2016.
Keto J; Hahtola S; Linna M; Väkevä L
BMC Health Serv Res; 2021 Feb; 21(1):166. PubMed ID: 33618714
[TBL] [Abstract][Full Text] [Related]
12. Combined modality treatment of cutaneous T cell lymphoma: results of a 6-year follow-up.
Winkler CF; Sausville EA; Ihde DC; Fischmann AB; Schechter GP; Kumar PP; Nibhanupdi JR; Minna JD; Makuch RW; Eddy JL
J Clin Oncol; 1986 Jul; 4(7):1094-100. PubMed ID: 3088220
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome.
Foss FM; Ihde DC; Breneman DL; Phelps RM; Fischmann AB; Schechter GP; Linnoila I; Breneman JC; Cotelingam JD; Ghosh BC
J Clin Oncol; 1992 Dec; 10(12):1907-13. PubMed ID: 1453206
[TBL] [Abstract][Full Text] [Related]
14. Mycosis fungoides: management with topical nitrogen mustard.
Hoppe RT; Abel EA; Deneau DG; Price NM
J Clin Oncol; 1987 Nov; 5(11):1796-803. PubMed ID: 3681368
[TBL] [Abstract][Full Text] [Related]
15. Advancements in the treatment of mycosis fungoides and Sézary syndrome: monoclonal antibodies, immunotherapies, and Janus kinase inhibitors.
Quadri I; Reneau JC; Hanel W; Chung CG
Front Immunol; 2023; 14():1291259. PubMed ID: 38022633
[TBL] [Abstract][Full Text] [Related]
16. Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome. Definition of three distinctive prognostic groups.
Sausville EA; Eddy JL; Makuch RW; Fischmann AB; Schechter GP; Matthews M; Glatstein E; Ihde DC; Kaye F; Veach SR
Ann Intern Med; 1988 Sep; 109(5):372-82. PubMed ID: 3408055
[TBL] [Abstract][Full Text] [Related]
17. Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma.
Roenigk HH; Kuzel TM; Skoutelis AP; Springer E; Yu G; Caro W; Gilyon K; Variakojis D; Kaul K; Bunn PA
J Invest Dermatol; 1990 Dec; 95(6 Suppl):198S-205S. PubMed ID: 2258636
[TBL] [Abstract][Full Text] [Related]
18. Recombinant interferon alfa-2a, an active agent in advanced cutaneous T-cell lymphomas.
Bunn PA; Ihde DC; Foon KA
Int J Cancer Suppl; 1987; 1():9-13. PubMed ID: 3305390
[TBL] [Abstract][Full Text] [Related]
19. Cutaneous T cell lymphoma differing from classical mycosis fungoides and Sézary syndrome: clinical, histological and immunohistochemical studies of six cases.
Maeda K; Takahashi M; Takatsuka N; Miyazawa H
J Dermatol; 1990 Apr; 17(4):226-34. PubMed ID: 2195088
[TBL] [Abstract][Full Text] [Related]
20. Risk of progression of early-stage mycosis fungoides, 10-year experience.
Ariza Gómez SA; Dubeibe Abril PA; Niebles Sincelejo OE; Reina HSL
An Bras Dermatol; 2024; 99(3):407-413. PubMed ID: 38395632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
